STOCK TITAN
  1. Home
  2. News
  3. GOSS

Gossamer Bio Inc - GOSS STOCK NEWS

Welcome to our dedicated news page for Gossamer Bio (Ticker: GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gossamer Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gossamer Bio's position in the market.

News
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
Rhea-AI Summary
Gossamer Bio, Inc. appoints Dr. Steven D. Nathan and Ms. Skye Drynan to its Board of Directors. Dr. Nathan brings medical expertise in pulmonary hypertension associated with interstitial lung disease, while Ms. Drynan contributes financial acumen from her background in biotechnology investment. The additions aim to enhance Gossamer's clinical program for seralutinib, positioning the company as a leader in treating rare forms of pulmonary hypertension.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
management
-
News
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Gossamer Bio, Inc. dosed the first PAH patient in the Phase 3 PROSERA Study, including Japan, with $296 million in cash equivalents. Faheem Hasnain, CEO, highlighted progress and potential in bringing seralutinib to market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Gossamer Bio, Inc. (Nasdaq: GOSS) announced the approval of non-qualified stock option awards for two new non-executive employees under the 2023 Employment Inducement Incentive Award Plan. The options have an exercise price of $0.85 per share and will vest over four years, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.16%
Tags
none
News
Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023
Rhea-AI Summary
Gossamer Bio, Inc. (Nasdaq: GOSS) will host a public conference call and webcast on December 18, 2023, at 8:30 am ET to discuss the latest seralutinib clinical data from the ongoing TORREY Phase 2 Open-Label Extension Study in PAH patients. Seralutinib is a tyrosine kinase inhibitor targeting PDGFRα/β, CSF1R, and c-KIT, specifically designed to be delivered via dry powder inhaler for the treatment of pulmonary hypertension.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.74%
Tags
conferences
-
News
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Gossamer Bio, Inc. (Nasdaq: GOSS) granted 1,500,000 stock options to Bob Smith, the newly appointed Chief Commercial Officer, with an exercise price of $0.969 per share. The options will vest over four years, subject to Mr. Smith’s continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
none
-
News
Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
Rhea-AI Summary
Gossamer Bio, Inc. (Nasdaq: GOSS) appoints Bob Smith as Chief Commercial Officer, leveraging his 30 years of pharmaceutical experience, including leadership at Merck and Actelion, to drive the commercialization of seralutinib for pulmonary arterial hypertension treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.3%
Tags
management
News
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors
Rhea-AI Summary
Gossamer Bio, Inc. (Nasdaq: GOSS) has appointed Dr. John Quisel, President and CEO of Disc Medicine, to its Board of Directors. Dr. Quisel's extensive experience in the biopharmaceutical industry and his strategic insights in the treatment of pulmonary arterial hypertension (PAH) are expected to enhance Gossamer's ability to bring seralutinib to patients. His successful track record and leadership roles at Disc Medicine and Acceleron Pharma demonstrate his expertise in building and growing biopharmaceutical companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
management
-
News
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Gossamer Bio, Inc. (Nasdaq: GOSS) reports $329 million in cash, cash equivalents & marketable securities, with Phase 3 PROSERA site activations ahead of schedule and first dosing expected in 4Q23. Additional data from TORREY Open-Label Extension also expected in 4Q23.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.56%
Tags
earnings
-
News
Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs
Rhea-AI Summary
Gossamer Bio announces the appointment of Dr. Rainer Zimmermann as Vice President of Medical Affairs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
none
News
Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023
Rhea-AI Summary
Gossamer Bio announces positive data on seralutinib for PAH treatment at ERS Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.71%
Tags
conferences
Stock GOSS logo
Gossamer Bio Inc

Nasdaq:GOSS

GOSS Rankings

#3828 Ranked by Market Cap
#5513 Ranked by Stock Gains
N/A Ranked by Dividends

GOSS Stock Data

201.94M
190.99M
2.25%
93.16%
4.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About GOSS

gossamer bio is a san diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. founded by the former receptos executive team, gossamer bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.